Drug delivery strategies for improved azole antifungal action

Bibliography

• Pfaller M, Wenzel R. The epidemiology of fungal infections. In: Elias EJ, McGinnis MR, Pfaller MA, editors, Clinical mycology. Elsevier Science: New York; 2003
   Google Scholar
• Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29(2):239-44
   PubMed Web of Science ®Google Scholar
• Pierard GE, Arrese JE, Quatresooz P, et al. Emerging therapeutic agents for onychomycosis. Expert Opin Emerging Drugs 2007;12(3):345-53
   PubMed Web of Science ®Google Scholar
• Chan OH, Stewart BH, Physicochemical and drug-delivery considerations for oral drug bioavailability. Drug Discov Today 1996;1(11):461-73
   Web of Science ®Google Scholar
• Canuto MM, Gutierrez F. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002;2(9):550-63
   PubMed Web of Science ®Google Scholar
• Zonios DI, Bennett JE. Update on azole antifungals. Semin Resp Crit Care 2008;29(2):198-210
   PubMed Web of Science ®Google Scholar
• Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1988;1(2):187-217
   PubMedGoogle Scholar
• Vanden Bossche H, Engelen M, Rochette F. Antifungal agents of use in animal health – chemical, biochemical and pharmacological aspects. J Vet Pharmacol Ther 2003;26(1):5-29
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994;331(20):1325-30
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004;38(2):161-89
   PubMed Web of Science ®Google Scholar
• Debruyne D, Clinical pharmacokinetics ol fluconazole in superficial and systemic mycoses. Clin Pharmacokinet 1997;33(1):52-77
   PubMed Web of Science ®Google Scholar
• Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 1985;28(5):648-53
   PubMed Web of Science ®Google Scholar
• Haneke E. Fluconazole levels in human epidermis and blister fluid. Br J Dermatol 1990;123(2):273-4
   PubMed Web of Science ®Google Scholar
• De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001;61:27-37
   PubMed Web of Science ®Google Scholar
• Cauwenbergh G, Degreef H, Heykants J, et al. Pharmacokinetic profile of orally-administered itraconazole in human-skin. J Am Acad Dermatol 1988;18(2):263-8
   PubMed Web of Science ®Google Scholar
• Hitchcock C, Pye G, Oliver G, et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro. In: 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995; Washington
   Google Scholar
• VFEND Pi, Package insert. VFEND Tablets/VFEND I.V. (voriconazole). 2002, New York: Pfizer Roerig
   Google Scholar
• Page RL, Schwiesow J, Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy 2007;27(2):290-8
   PubMed Web of Science ®Google Scholar
• Raad I, Chapman S, Bradsher R, et al. Posaconazole (POS) salvage therapy for invasive fungal infections (IFI). In: Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004; Washington, DC
   Google Scholar
• Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50(2):658-66
   PubMed Web of Science ®Google Scholar
• Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5(12):775-85
   PubMed Web of Science ®Google Scholar
• Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006;50(5):1881-3
   PubMed Web of Science ®Google Scholar
• Degreef HJ, Dedoncker PRG. Current therapy of dermatophytosis. J Am Acad Dermatol 1994;31(3):S25-30
   PubMed Web of Science ®Google Scholar
• Ghosh TK, Pfister WR, Yum SI. Transdermal and topical drug delivery systems. Buffalo Grove, IL: Interpharm Press; 1997
   Google Scholar
• Alberti I, Kalia YN, Naik A, et al. Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo. Int J Pharm 2001;219(1-2):11-9
   PubMed Web of Science ®Google Scholar
• Kemken J, Ziegler A, Muller BW. Influence of supersaturation on the pharmacodynamic effect of bupranolol after dermal administration using microemulsions as vehicle. Pharm Res 1992;9(4):554-8
   PubMed Web of Science ®Google Scholar
• Hadgraft J. Passive enhancement strategies in topical and transdermal drug delivery. Int J Pharm 1999;184(1):1-6
   PubMed Web of Science ®Google Scholar
• Kondo S, Yamasaki-Konishi H, Sugimoto I. Enhancement of transdermal delivery by superfluous thermodynamic potential. II. In vitro–in vivo correlation of percutaneous nifedipine transport. J Pharmacobio Dynamics 1987;10(11):662-8
   PubMedGoogle Scholar
• El Laithy HM, El-Shaboury KM. The development of Cutina lipogels and gel microemulsion for topical administration of fluconazole. AAPS PharmSciTech 2002;3(4):E35
   PubMedGoogle Scholar
• Rojanasakul Y, Wang LY, Bhat M, et al. The transport barrier of epithelia – a comparative study on membrane-permeability and charge selectivity in the rabbit. Pharm Res 1992;9(8):1029-34
   PubMed Web of Science ®Google Scholar
• Piemi MPY, Korner D, Benita S, et al. Positively and negatively charged submicron emulsions for enhanced topical delivery of antifungal drugs. J Control Release 1999;58(2):177-87
   PubMed Web of Science ®Google Scholar
• Kim MK, Chung SJ, Lee MH, et al. Targeted and sustained delivery of hydrocortisone to normal and stratum corneum-removed skin without enhanced skin absorption using a liposome gel. J Control Release 1997;46(3):243-51
   Web of Science ®Google Scholar
• Yoshioka T, Sternberg B, Florence AT. Preparation and properties of vesicles (Niosomes) of sorbitan monoesters (Span-20, Span-40, Span-60 and Span-80) and a Sorbitan Triester (Span-85). Int J Pharm 1994;105(1):1-6
   Web of Science ®Google Scholar
• Fang JY, Hong CT, Chiu WT, et al. Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm 2001;219(1-2):61-72
   PubMed Web of Science ®Google Scholar
• Ning MY, Guo YZ, Pan HZ, et al. Preparation, in vitro and in vivo evaluation of liposomal/niosomal gel delivery systems for clotrimazole. Drug Dev Ind Pharm 2005;31(4-5):375-83
   PubMed Web of Science ®Google Scholar
• Muller RH, Ruhl D, Runge S, et al. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res 1997;14(4):458-62
   PubMed Web of Science ®Google Scholar
• Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm 2000;50(1):161-77
   PubMed Web of Science ®Google Scholar
• Wissing SA, Lippacher A, Muller RH. Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J Cosmet Sci 2001;52(5):313-24
   PubMed Web of Science ®Google Scholar
• Souto EB, Wissing SA, Barbosa CM, et al. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004;278(1):71-7
   PubMed Web of Science ®Google Scholar
• Souto EB, Muller RH. The use of SLN and NLC as topical particulate carriers for imidazole antifungal agents. Pharmazie 2006;61(5):431-7
   PubMed Web of Science ®Google Scholar
• Sanna V, Gavini E, Cossu M, et al. Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in vitro characterization, ex vivo and in vivo studies. J Pharm Pharmacol 2007;59(8):1057-64
   PubMed Web of Science ®Google Scholar
• Bouckaert S, Schautteet H, Lefebvre RA, et al. Comparison of salivary miconazole concentrations after administration of a bioadhesive slow-release buccal tablet and an oral gel. Eur J Clin Pharmacol 1992;43(2):137-40
   PubMed Web of Science ®Google Scholar
• Codd JE, Deasy PB. Formulation development and in vivo evaluation of a novel bioadhesive lozenge containing a synergistic combination of antifungal agents. Int J Pharm 1998;173(1-2):13-24
   Web of Science ®Google Scholar
• Karasulu HY, Hilmioglu S, Metin DY, et al. Efficacy of a new ketoconazole bioadhesive vaginal tablet on Candida albicans. Farmaco 2004;59(2):163-7
   PubMedGoogle Scholar
• Wang L, Tang X. A novel ketoconazole bioadhesive effervescent tablet for vaginal delivery: design, in vitro and ‘in vivo’ evaluation. Int J Pharm 2008;350(1-2):181-7
   PubMed Web of Science ®Google Scholar
• Francois M, Snoeckx E, Putteman P, et al. A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. Aaps Pharmsci 2003;5(1):E5
   PubMedGoogle Scholar
• Furneri PM, Corsello S, Masellis G, et al. Econazole–polycarbophil, a new delivery system for topical therapy: microbiological and clinical results on vaginal candidiasis. J Chemother 2008;20(3):336-40
   PubMed Web of Science ®Google Scholar
• Mididoddi PK, Repka MA. Characterization of hot-melt extruded drug delivery systems for onychomycosis. Eur J Pharm Biopharm 2007;66(1):95-105
   PubMed Web of Science ®Google Scholar
• Trey SM, Wicks DA, Mididoddi PK, et al. Delivery of itraconazole from extruded HPC films. Drug Dev Ind Pharm 2007;33(7):727-35
   PubMed Web of Science ®Google Scholar
• Hui XY, Chan TCK, Barbadillo S, et al. Enhanced econazole penetration into human nail by 2-n-nonyl-1,3-dioxolane. J Pharm Sci 2003;92(1):142-8
   PubMed Web of Science ®Google Scholar
• Baran R, Coquard F. Combination of fluconazole and urea in a nail lacquer for treating onychomycosis. J Dermatol Treat 2005;16(1):52-5
   PubMed Web of Science ®Google Scholar
• Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins .1. Drug solubilization and stabilization. J Pharm Sci 1996;85(10):1017-25
   PubMed Web of Science ®Google Scholar
• Brewster ME, Vandecruys R, Verreck G, et al. Supersaturating drug delivery systems: effect of hydrophilic cyclodextrins and other excipients on the formation and stabilization of supersaturated drug solutions. Pharmazie 2008;63(3):217-20
   PubMed Web of Science ®Google Scholar
• Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother 1992;36(2):477-80
   PubMed Web of Science ®Google Scholar
• Pedersen M. Isolation and antimycotic effect of a genuine miconazole beta-cyclodextrin complex. Eur J Pharm Biopharm 1994;40(1):19-23
   Web of Science ®Google Scholar
• Tenjarla S, Puranajoti P, Kasina R, et al. Preparation, characterization, and evaluation of miconazole-cyclodextrin complexes for improved oral and topical delivery. J pharm Sci 1998;87(4):425-9
   PubMed Web of Science ®Google Scholar
• Taneri F, Guneri T, Aigner Z, et al. Improvement of the physicochemical properties of clotrimazole by cyclodextrin complexation. J Incl Phenom Macro 2003;46(1-2):1-13
   Web of Science ®Google Scholar
• Taneri F, Guneri T, Aigner Z, et al. Improvement in the physicochemical properties of ketoconazole through complexation with cyclodextrin derivatives. J Incl Phenom Macro 2002;44(1-4):257-60
   Web of Science ®Google Scholar
• Taneri F, Guneri T, Aigner Z, et al. Influence of cyclodextrin complexation on the physicochemical and biopharmaceutical properties of ketoconazole. J Incl Phenom Macro 2003;47(1-2):15-23
   Web of Science ®Google Scholar
• Yong CS, Li DX, Prabagar B, et al. The effect of beta-cyclodextrin complexation on the bioavailability and hepatotoxicity of clotrimazole. Pharmazie 2007;62(10):756-9
   PubMed Web of Science ®Google Scholar
• Pedersen M, Bjerregaard S, Jacobsen J, et al. A genuine clotrimazole gamma-cyclodextrin inclusion complex-isolation, antimycotic activity, toxicity and an unusual dissolution rate. Int J Pharm 1998;176(1):121-31
   Web of Science ®Google Scholar
• Peeters J, Neeskens P, Tollenaere JP, et al. Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci 2002;91(6):1414-22
   PubMed Web of Science ®Google Scholar
• Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998;35(6):461-73
   PubMed Web of Science ®Google Scholar
• Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male-volunteers. Antimicrob Agents Chemother 1993;37(4):778-84
   PubMed Web of Science ®Google Scholar
• Sporanox® pl, Package insert. Sporanox capsules/oral solution/Sporanox I.V. (itraconazole)
   Google Scholar
• Willems L, van der Geest R, de Beule K. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001;26(3):159-69
   PubMed Web of Science ®Google Scholar
• Gould S, Scott RC. 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol 2005;43(10):1451-9
   PubMed Web of Science ®Google Scholar
• Stella VJ, He Q. Cyclodextrins. Toxicol Pathol 2008;36(1):30-42
   PubMed Web of Science ®Google Scholar
• VandeVelde VJS, VanPeer AP, Heykants JJP, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy 1996;16(3):424-8
   PubMed Web of Science ®Google Scholar
• Buchanan CM, Buchanan NL, Edgar KJ, et al. Pharmacokinetics of itraconazole after intravenous and oral dosing of itraconazole-cyclodextrin formulations. J Pharm Sci 2007;96(11):3100-16
   PubMed Web of Science ®Google Scholar
• Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004;58(3):173-82
   PubMed Web of Science ®Google Scholar
• Hong JY, Kim JK, Song YK, et al. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J Control Release 2006;110(2):332-8
   PubMed Web of Science ®Google Scholar
• Woo JS, Song YK, Hong JY, et al. Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. Eur J Pharm Sci 2008;33(2):159-65
   PubMed Web of Science ®Google Scholar
• FDA, Guidance for Industry – Nonclinical Studies for the Safety evaluation of Pharmaceutical Excipients, F.a.D. Administration, Editor, 2005
   Google Scholar
• Park MJ, Ren S, Lee BJ. In vitro and in vivo comparative study of itiraconazole bioavailability when formulated in highly soluble self-emulsifying system and in solid dispersion. Biopharm Drug Dispos 2007;28(4):199-207
   PubMed Web of Science ®Google Scholar
• Jaiswal J, Gupta SK, Kreuter J. Preparation of biodegradable cyclosporine nanoparticles by high-pressure emulsification-solvent evaporation process. J Control Release 2004;96(1):169-78
   PubMed Web of Science ®Google Scholar
• Pandey R, Ahmad Z, Sharma S, et al. Nano-encapsulation of azole antifungals: Potential applications to improve oral drug delivery. Int J Pharm 2005;301(1-2):268-76
   PubMed Web of Science ®Google Scholar
• Peng HS, Liu XJ, Lv GX, et al. Voriconazole into PLGA nanoparticles: Improving agglomeration and antifungal efficacy. Int J Pharm 2008;352(1-2):29-35
   PubMed Web of Science ®Google Scholar
• Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50(1):47-60
   PubMed Web of Science ®Google Scholar
• Kapsi SG, Ayres JW. Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability. Int J Pharm 2001;229(1-2):193-203
   PubMed Web of Science ®Google Scholar
• Janssens S, Nagels S, de Armas HN, et al. Formulation and characterization of ternary solid dispersions made up of Itraconazole and two excipients, TPGS 1000 and PVPVA 64, that were selected based on a supersaturation screening study. Eur J Pharm Biopharm 2008;69(1):158-66
   PubMed Web of Science ®Google Scholar
• Six K, Daems T, de Hoon J, et al. Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. Eur J Pharm Sci 2005;24(2-3):179-86
   PubMed Web of Science ®Google Scholar
• Kwon K, Kim ST, Ahn CH, et al. The efficacy and safety of short-term therapy with itraconazole melt-extrusion tablet in the hyperkeratotic type of Tinea pedis and/or Tinea manus. Korean J Med Mycol 2000;5(1):13-9
   Google Scholar
• Moon K, Koh JK, Cho BK, et al. Efficacy of itraconazole melt-extrusion tablet one-week therapy in treatment of hyperkeratotic type of Tinea pedis and/or Tinea manus. Korean J Dermatol 1999;37(8):1047-56
   Google Scholar
• Miller DA, McConville JT, Yang W, et al. Hot-melt extrusion for enhanced delivery of drug particles. J Pharm Sci 2007;96(2):361-76
   PubMed Web of Science ®Google Scholar
• Miller DA, DiNunzio JC, Yang W, et al. Targeted intestinal delivery of supersaturated itraconazole for improved oral absorption. Pharm Res 2008;25(6):1450-59
   PubMed Web of Science ®Google Scholar
• Leconte P, Joly V, Saintjulien L, et al. Tissue distribution and antifungal effect of liposomal itraconazole in experimental cryptococcosis and pulmonary aspergillosis. Am Rev Respir Dis 1992;145(2):424-9
   PubMedGoogle Scholar
• OrthoBiotech. Available from: http://www.fda.gov/Cder/Drug/shortages/Sporanox-10-11-2007.pdf 2007 [cited].
   Google Scholar
• Kipp JE. Using NANOEDGE in the rapid development of water-insoluble drug formulations. In: The Seventh Annual Drug Delivery Partnerships Conference/Institute for International Research (IIR); 2003; San Diego
   Google Scholar
• Rabinow B, Kipp J, Papadopoulos P, et al. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm 2007;339(1-2):251-60
   PubMed Web of Science ®Google Scholar
• Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly water-soluble compounds. Eur J Pharm Sci 2003;18(2):113-20
   PubMed Web of Science ®Google Scholar
• Mouton JW, van Peer A, de Beule K, et al. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother 2006;50(12):4096-102
   PubMed Web of Science ®Google Scholar
• Muller RH, Schmidt S, Buttle I, et al. SolEmuls (R) – novel technology for the formulation of i.v. emulsions with poorly soluble drugs. Int J Pharm 2004;269(2):293-302
   PubMed Web of Science ®Google Scholar
• Akkar A, Muller RH. Intravenous itraconazole emulsions produced by SolEmuls technology. Eur J Pharm Biopharm 2003;56(1):29-36
   PubMed Web of Science ®Google Scholar
• Barratt G. Colloidal drug carriers: achievements and perspectives. Cell Mol Life Sci 2003;60(1):21-37
   PubMed Web of Science ®Google Scholar
• de Assis DN, Mosqueira VCF, Vilela JMC, et al. Release profiles and morphological characterization by atomic force microscopy and photon correlation spectroscopy of (99m)Technetium-fluconazole nanocapsules. Int J Pharm 2008;349(1-2):152-60
   PubMedGoogle Scholar
• Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34(7):909-17
   PubMed Web of Science ®Google Scholar
• Elder EJ, Hitt JE, Rogers TL, et al. Particle engineering of poorly water soluble drugs by controlled precipitation. Acs Sym Ser 2006;924:292-304
   Google Scholar
• Vaughn JM, Gao X, Yacaman MJ, et al. Comparison of powder produced by evaporative precipitation into aqueous solution (EPAS) and spray freezing into liquid (SFL) technologies using novel Z-contrast STEM and complimentary techniques. Eur J Pharm Biopharm 2005;60(1):81-9
   PubMed Web of Science ®Google Scholar
• Overhoff KA, Engstrom JD, Chen B, et al. Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs. Eur J Pharm Biopharm 2007;65(1):57-67
   PubMed Web of Science ®Google Scholar
• Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998;85(2):379-85
   PubMed Web of Science ®Google Scholar
• McConville JT, Overhoff KA, Sinswat P, et al. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res 2006;23(5):901-11
   PubMed Web of Science ®Google Scholar
• McConville JT, Williams RO, Carvalho TC, et al. Design and evaluation of a restraint-free small animal inhalation dosing chamber. Drug Dev Ind Pharm 2005;31(1):35-42
   PubMed Web of Science ®Google Scholar
• Sobel JD. Practice guidelines for the treatment of fungal infections. For the Mycoses Study Group. Infectious Diseases Society of America. Clin Infect Dis 2000;30(4:652
   PubMed Web of Science ®Google Scholar
• Hoeben BJ, Burgess DS, McConville JT, et al. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006;50(4):1552-4
   PubMed Web of Science ®Google Scholar
• Alvarez CA, Wiederhold NP, McConville JT, et al. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J Infect 2007;55(1):68-74
   PubMed Web of Science ®Google Scholar
• McConville JT, Wiederhold NP. Invasive pulmonary aspergillosis: therapeutic and prophylactic strategies. In: Williams RO 3rd, Taft DR, McConville JT, editors, Advanced drug formulation design to optimize therapeutic outcomes. Informa Healthcare: New York, NY; 2007. p. 53-80
   Google Scholar
• Yang W, Tam J, Miller DA, et al. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm 2008;361(1-2):177-88
   PubMed Web of Science ®Google Scholar
• Liu FY, Shao Z, Kildsig DO, et al. Pulmonary delivery of free and liposomal insulin. Pharm Res 1993;10(2):228-32
   PubMed Web of Science ®Google Scholar
• Yang W, Peters JI, Williams RO 3rd. Inhaled nanoparticles – a current review. Int J Pharm 2008;356(1-2):239-47
   PubMed Web of Science ®Google Scholar